Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Editor's Note
Over the past couple of years we have seen the use of SGLT-2 Inhibitors increase and we now have 3 different molecules to choose from. There have been studies that show the cardiovascular benefits of the class as well as the benefit of combining them with GLP-1 analogs. This year the big thing at the ADA meeting in Orlando was the use of SGLT-2 Inhibitors with Insulin, and in this Therapy Edition, we have the results of one of those studies.
We also would like to call your attention to the “evolution” of SGLT Therapy. As we all have seen, once a new class is introduced there is a rush to find the second generation of the original products. We have seen that with secretagogues, going from Chlorpropamide to Glipizde, from Pork Regular Insulin to Lispro, and from NPH to Glargine. This new generation of SGLT Therapy is getting ready to be released, as we are about to see the first Dual SGLT released. To learn what a Dual SGLT is, click here
Dave Joffe
Editor-in-chief
Sotagliflozin to be reviewed by the FDA as possible oral adjunct for people with insulin-treated type 1 diabetes.
The different mechanisms of action of these two drugs make them an excellent combination in the treatment of patients with type 2 diabetes mellitus (T2DM).
DEPICT-2 study of more than 800 people worldwide indicates positive results without added risk of severe hypoglycemia, but slight increase in DKA events.
With over 6 million possible combinations, it is difficult to come up with the best treatment for each patient. The phase III DURATION-8 trial may help you to decide.